Scilex Holding Company
SCLX
Rank in Stocks
#28102
Scilex Holding Company is a biopharmaceutical enterprise that specializes in... Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.
Share Price
$1.74
Last synced: 2026-11-09
Market Cap
$12.24M
Change (1 day)
2.35%
Change (1 year)
-90.80%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Scilex Holding Company (SCLX)
Category
Healthcare
Operating Margin for Scilex Holding Company (SCLX)
Operating Margin as of November 2026 TTM: -903.52%
According to Scilex Holding Company's latest financial reports, its current operating margin (TTM) is -903.52%. At the end of 2025 the company had an operating margin of -900.09%.
Operating Margin history for Scilex Holding Company from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -903.52% | 0.38% |
| 2025 | -900.09% | 510.77% |
| 2024 | -147.37% | -34.66% |
| 2023 | -225.55% | 69.42% |
| 2022 | -133.13% | 16.33% |
| 2021 | -114.44% | -23.53% |
| 2020 | -149.65% | -77.31% |
| 2019 | -659.42% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 46.07% | -100.05% |
US
|
|
| 25.70% | -100.03% |
US
|
|
| 35.53% | -100.04% |
US
|
|
| 16.24% | -100.02% |
US
|
|
| 31.92% | -100.04% |
CH
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Scilex Holding Company's operating margin
What is Scilex Holding Company's operating margin?
Scilex Holding Company's operating margin is -903.52%, as of Nov 2026.
What was Scilex Holding Company's operating margin in 2025?
In 2025, Scilex Holding Company's operating margin was -900.09%, compared with -147.37% in 2024.
How has Scilex Holding Company's operating margin changed since 2020?
From 2020 to 2025, Scilex Holding Company's operating margin was highest in 2021 (-114.44%) and lowest in 2025 (-900.09%).
How does Scilex Holding Company's operating margin compare with similar companies?
Scilex Holding Company's operating margin (-903.52%) is lower than that of all 5 similar companies listed above. The highest among them is Eli Lilly and Company, with 46.07%.